tradingkey.logo

Quantum BioPharma Ltd

QNTM
8.890USD
+0.070+0.79%
收盘 12/19, 16:00美东报价延迟15分钟
33.93M总市值
亏损市盈率 TTM

Quantum BioPharma Ltd

8.890
+0.070+0.79%

关于 Quantum BioPharma Ltd 公司

Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. The Company has also licensed unbuzzd, a formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving individuals from the effects of alcohol consumption. It maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.

Quantum BioPharma Ltd简介

公司代码QNTM
公司名称Quantum BioPharma Ltd
上市日期May 29, 2018
CEOKotra (Lakshmi P)
员工数量- -
证券类型Ordinary Share
年结日May 29
公司地址55 University Ave. , Suite 1003
城市TORONTO
上市交易所NASDAQ OMX - NASDAQ BASIC
国家Canada
邮编M5J 2H7
电话14168548884
网址https://www.quantumbiopharma.com/
公司代码QNTM
上市日期May 29, 2018
CEOKotra (Lakshmi P)

Quantum BioPharma Ltd公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Zeeshan Saeed
Mr. Zeeshan Saeed
Executive Co-Chairman of the Board, President, Chief Executive Officer
Executive Co-Chairman of the Board, President, Chief Executive Officer
118.41K
+0.25%
Mr. Donal Carroll, CPA
Mr. Donal Carroll, CPA
Chief Financial Officer
Chief Financial Officer
90.41K
+9.30%
Mr. Anthony Durkacz
Mr. Anthony Durkacz
Co-Executive Chairman of the Board
Co-Executive Chairman of the Board
29.11K
-72.73%
Mr. Adnan Bashir
Mr. Adnan Bashir
Independent Director
Independent Director
--
--
Mr. Joseph L. Romano
Mr. Joseph L. Romano
Director
Director
--
--
Mr. Lawrence (Larry) Latowsky
Mr. Lawrence (Larry) Latowsky
Independent Director
Independent Director
--
--
Mr. Kevin Cassidy
Mr. Kevin Cassidy
Vice President - Quality of Lucid
Vice President - Quality of Lucid
--
--
Dr. Andrzej Chruscinski, M.D., Ph.D.
Dr. Andrzej Chruscinski, M.D., Ph.D.
Vice President - Clinical and Scientific Affairs
Vice President - Clinical and Scientific Affairs
--
-100.00%
Dr. Lakshmi P. Kotra, Ph.D.
Dr. Lakshmi P. Kotra, Ph.D.
Chief Executive Officer of Lucid, Director, President of FSD Biosciences and CEO of FSD Australia
Chief Executive Officer of Lucid, Director, President of FSD Biosciences and CEO of FSD Australia
--
--
Dr. Eric Hoskins, M.D.
Dr. Eric Hoskins, M.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Zeeshan Saeed
Mr. Zeeshan Saeed
Executive Co-Chairman of the Board, President, Chief Executive Officer
Executive Co-Chairman of the Board, President, Chief Executive Officer
118.41K
+0.25%
Mr. Donal Carroll, CPA
Mr. Donal Carroll, CPA
Chief Financial Officer
Chief Financial Officer
90.41K
+9.30%
Mr. Anthony Durkacz
Mr. Anthony Durkacz
Co-Executive Chairman of the Board
Co-Executive Chairman of the Board
29.11K
-72.73%
Mr. Adnan Bashir
Mr. Adnan Bashir
Independent Director
Independent Director
--
--
Mr. Joseph L. Romano
Mr. Joseph L. Romano
Director
Director
--
--
Mr. Lawrence (Larry) Latowsky
Mr. Lawrence (Larry) Latowsky
Independent Director
Independent Director
--
--

收入明细

由于公司未披露,未能获取相关数据
由于公司未披露,未能获取相关数据
业务
地区
由于公司未披露,未能获取相关数据

股东统计

更新时间: 12月2日 周二
更新时间: 12月2日 周二
持股股东
股东类型
持股股东
持股股东
占比
Malone Wealth Ventures LLC
27.43%
Saeed (Zeeshan)
3.10%
Carroll (Donal)
2.37%
Lynch (Terrence)
1.35%
AdvisorShares Investments, LLC
0.98%
其他
64.77%
持股股东
持股股东
占比
Malone Wealth Ventures LLC
27.43%
Saeed (Zeeshan)
3.10%
Carroll (Donal)
2.37%
Lynch (Terrence)
1.35%
AdvisorShares Investments, LLC
0.98%
其他
64.77%
股东类型
持股股东
占比
Investment Advisor
29.12%
Individual Investor
8.54%
Investment Advisor/Hedge Fund
1.36%
Corporation
0.37%
Research Firm
0.09%
其他
60.52%

机构持股

更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
40
1.17M
30.70%
+254.90K
2025Q2
50
1.04M
35.99%
+612.85K
2025Q1
50
413.46K
17.05%
-229.58K
2024Q4
44
604.87K
28.35%
+138.76K
2024Q3
45
583.17K
30.09%
+414.87K
2024Q2
43
126.91K
14.87%
-21.03K
2024Q1
47
105.72K
14.06%
-57.49K
2023Q4
49
159.35K
26.32%
+20.22K
2023Q3
52
164.58K
27.23%
+48.13K
2023Q2
52
164.21K
27.10%
+38.85K
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
Malone Wealth Ventures LLC
1.05M
27.43%
+217.43K
+26.20%
Sep 06, 2025
Saeed (Zeeshan)
118.41K
3.1%
+300.00
+0.25%
Aug 14, 2025
Carroll (Donal)
90.41K
2.37%
+7.69K
+9.30%
Apr 03, 2025
Lynch (Terrence)
51.42K
1.35%
+51.42K
--
Aug 14, 2025
AdvisorShares Investments, LLC
36.99K
0.97%
-12.00K
-24.49%
Jun 30, 2025
Kotra (Lakshmi)
29.57K
0.77%
--
--
Aug 14, 2025
Durkacz (Anthony)
106.76K
2.8%
--
--
Aug 14, 2025
UBS Financial Services, Inc.
45.88K
1.2%
+44.27K
+2742.81%
Jun 30, 2025
Saeed (Rehan)
6.79K
0.18%
-2.15K
-24.09%
Dec 31, 2024
查看更多

持股ETF

更新时间: 12月2日 周二
更新时间: 12月2日 周二
机构名称
占比
AdvisorShares Psychedelics ETF
6.05%
AdvisorShares Psychedelics ETF
占比6.05%

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
类型
比率
Aug 12, 2024
Merger
65→1
Aug 12, 2024
Merger
65→1
Aug 12, 2024
Merger
65→1
Aug 12, 2024
Merger
65→1
公告日期
类型
比率
Aug 12, 2024
Merger
65→1
Aug 12, 2024
Merger
65→1
Aug 12, 2024
Merger
65→1
Aug 12, 2024
Merger
65→1

常见问题

Quantum BioPharma Ltd的前五大股东是谁?

Quantum BioPharma Ltd 的前五大股东如下:
Malone Wealth Ventures LLC持有股份:1.05M,占总股份比例:27.43%。
Saeed (Zeeshan)持有股份:118.41K,占总股份比例:3.10%。
Carroll (Donal)持有股份:90.41K,占总股份比例:2.37%。
Lynch (Terrence)持有股份:51.42K,占总股份比例:1.35%。
AdvisorShares Investments, LLC持有股份:36.99K,占总股份比例:0.97%。

Quantum BioPharma Ltd的前三大股东类型是什么?

Quantum BioPharma Ltd 的前三大股东类型分别是:
Malone Wealth Ventures LLC
Saeed (Zeeshan)
Carroll (Donal)

有多少机构持有Quantum BioPharma Ltd(QNTM)的股份?

截至2025Q3,共有40家机构持有Quantum BioPharma Ltd的股份,合计持有的股份价值约为1.17M,占公司总股份的30.70%。与2025Q2相比,机构持股有所增加,增幅为-5.29%。

哪个业务部门对Quantum BioPharma Ltd的收入贡献最大?

在--,--业务部门对Quantum BioPharma Ltd的收入贡献最大,创收--,占总收入的--%。
KeyAI